Browse the evidence

Regaining weight after discontinuing GLP-1 receptor agonists is stigmatized to a similar degree as regaining weight after discontinuing diet and exercise, and both are stigmatized more than maintaining weight loss.

If you regain weight after stopping GLP-1s, you may face social judgment similar to that faced by those who regain weight after dieting. This stigma is not unique to medication users. Recognize that weight regain is a common outcome and does not reflect a lack of character. Focus on sustainable health practices rather than avoiding social judgment.

A unimolecular antibody-peptide conjugate combining GIP receptor antagonism and GLP-1 receptor agonism (AMG 133) produces significant, sustained body weight loss in obese non-human primates when administered via once-weekly subcutaneous injection.

This research identifies AMG 133 as a potent obesity treatment in primates, achieving nearly 17% body weight loss with once-weekly injections. For humans, this suggests a future therapy that is more convenient than daily injections and potentially better tolerated than current single-target GLP-1 drugs, though it is not yet available for clinical use.

Retatrutide, a triple incretin agonist, alleviates adipose tissue fibrosis and dysfunction by reprogramming lipid metabolism and suppressing inflammatory pathways, rather than solely reducing fat mass.

Retatrutide is a potent injectable medication for obesity that works by fundamentally changing how fat tissue functions—reducing inflammation and fibrosis and improving metabolic health—rather than just suppressing appetite. It requires regular injections (every 3 days) and is most effective for individuals with significant diet-induced metabolic dysfunction.

Bariatric surgery (specifically Roux-en-Y Gastric Bypass and Sleeve Gastrectomy) is the most effective intervention for sustained weight loss and metabolic improvement, significantly altering gut microbiota diversity and reducing systemic inflammation.

Bariatric surgery, such as Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, offers the most significant and durable weight loss for severe obesity. It works by restricting stomach size and altering gut hormones and microbiota. Patients must commit to lifelong vitamin supplementation to prevent deficiencies.

In Heart Failure with Reduced Ejection Fraction (HFrEF), NuSH therapies show promise in reducing cardiovascular mortality and MACE, but require cautious patient selection and monitoring due to potential chronotropic effects (increased heart rate) and arrhythmia risks observed with earlier generation agents.

For heart failure with reduced ejection fraction (HFrEF), NuSH therapies are not yet a standard first-line treatment due to safety concerns like increased heart rate. However, recent real-world data suggests they may significantly reduce mortality in stable patients. If your doctor considers this, ensure you are clinically stable, have a normal resting heart rate, and are monitored closely. It is crucial to combine this therapy with resistance training and high protein intake to prevent muscle loss, which can be a side effect of rapid weight loss.

Fasting serum beta-hydroxybutyrate levels increased from a median of 95 μmoL/l to 185 μmoL/l over eight weeks.

Increased ketone levels can be expected with low-energy meal replacement diets.

Tirzepatide may result in an increase in non-serious adverse events (risk ratio 1.33, 95% CI 1.03 to 1.71) compared to placebo.

Clinicians should monitor for non-serious adverse events when prescribing tirzepatide.

The rates of CVD and death are higher in men compared to women and in rural compared to urban areas.

Public health interventions should target men and rural populations to reduce CVD incidence.

Specific gut microbial metabolites (SCFAs, Bile Acids, Tryptophan derivatives) stimulate GLP-1 secretion from intestinal L cells via specific receptors (FFAR2/3, TGR5, GPR142).

Consuming fiber (for SCFAs), specific fermented foods (for BAs), and tryptophan-rich foods can naturally boost GLP-1 by activating specific gut receptors. This supports metabolic and musculoskeletal health.

Cardiovascular disease (CVD) was the most common cause of death in South Asia, accounting for 35.5% of deaths.

Health policies should prioritize CVD prevention strategies in South Asia.

Rural areas had a higher incidence of CVD (5.41 per 1000 person-years) and a higher mortality rate (10.27 per 1000 person-years) compared to urban areas.

Targeted interventions in rural areas may be necessary to reduce CVD incidence and mortality.

Cardiovascular disease (CVD), cancer, and respiratory diseases account for over two-thirds of deaths in South America.

Health interventions should focus on CVD, cancer, and respiratory diseases to reduce mortality.

Greater hypothalamic inflammation and gliosis may predict adiposity gain and worsening insulin sensitivity.

Monitoring hypothalamic inflammation could be important for predicting weight gain and metabolic decline.

GLP-1 receptor agonists exert tissue-protective effects across multiple organs (pancreas, heart, liver, adipose, muscle, kidney, brain) primarily by driving mitochondrial remodeling, including improved biogenesis, quality control, and reduced oxidative stress.

GLP-1 medications (like semaglutide or liraglutide) do more than just help you lose weight; they actively improve the energy-producing centers (mitochondria) in your heart, liver, and other organs. This cellular repair helps protect these organs from damage, offering benefits that go beyond simple calorie reduction.

In pancreatic beta cells, GLP-1 receptor agonists directly protect against apoptosis and improve insulin secretion by enhancing mitochondrial ATP production, reducing oxidative stress, and promoting autophagy.

For people with Type 2 Diabetes, GLP-1 drugs help preserve the insulin-producing cells in the pancreas by keeping their energy factories (mitochondria) healthy and reducing cellular stress. This helps maintain the body's natural ability to produce insulin.

Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice.

Practitioners should stay informed about new pharmacological options for obesity management.

Incretin therapies could ameliorate fatty liver disease, chronic inflammation, sleep apnea, and possibly degenerative bone disorders and cognitive decline.

Incretin therapies may be considered for patients with these co-morbidities, pending further research.

GLP-1 receptor agonists exert direct antihypertensive effects independent of weight loss by modulating the sympathetic nervous system, improving endothelial function, enhancing renal sodium excretion, and suppressing the renin-angiotensin-aldosterone system.

Even without losing weight, GLP-1 medications help lower blood pressure by directly relaxing blood vessels, helping your kidneys excrete more sodium, and calming the nervous system signals that raise blood pressure. They also reduce the activity of hormones that constrict blood vessels.

A nomogram was established and validated for predicting the risk of type 2 diabetes in obese patients with non-alcoholic fatty liver disease.

Clinicians can use this nomogram for risk stratification in obese NAFLD patients.

The nomogram was constructed using five independent predictors selected from 17 variables.

Understanding the predictors can help in tailoring prevention strategies.

The model demonstrated good predictive power as indicated by the AUC values at different time points.

The nomogram can be reliably used in clinical settings for risk assessment.

There are predisposing risk factors for type 2 diabetes that can be reviewed.

Understanding risk factors can help in tailoring prevention strategies.

Overall low-carbohydrate diet (LCD) scores were not associated with mortality in the whole population of the study.

Practitioners should note that overall LCD scores do not predict mortality risk in this population.

There are predisposing risk factors for type 2 diabetes that can be reviewed.

Understanding risk factors can help in tailoring prevention strategies for individuals.